In the dose expansion phase of its DREAMM-1 phase I/II study of GSK2857916, the antibody-drug conjugate demonstrated a 60% response rate and median progression-free survival of 7.9 months
Showing 25 of 1928
ValiRx said its VAL401 anti-cancer compound had a “statistically significant” improvement in overall survival for patients with non-small cell lung cancer
"Abzena continues on its growth trajectory that, enabled by the investment secured this year and execution of the investment plans across our international business, is helping to establish Abzena as a significant solution provider for biopharmaceutical development of meaningful scale and impact."
Allergy already has injectable vaccines for dust mites and tree and grass pollen, but it has brought in Ergomed to take the tablet formulations through clinical trials
Cereal Ingredients Inc will incorporate SlimBiome into their range of cereal and protein-based particulates which are used in food products such as cakes, cookies and crackers
Parsortix harvests circulating tumour cells (CTCs) from blood- a tell-tale early sign of the disease.
High blood pressure, or hypertension, hardens the arteries and increases the risk of heart disease
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
The FTSE 250 listed packaging firm saw its pre-tax profit fall to £144mln for the six months to October 31, down from £146.0mln a year earlier, mainly due to an increase in one-off costs
People who have undergone stem cell transplants typically have weaker immune systems, which makes them more susceptible to viruses such as shingles
Smith & Nephew will pay US$125mln for Rotation Medical plus up to a further US$85mln over the next five years, contingent on financial performance
Former Express Dairies and Arla Foods chief executive Neil Davidson will take over from Adam Reynolds next month
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets
John Dawson, Alliance Pharma's chief executive, said: "The acquisition will be immediately earnings enhancing, accretive to our underlying return on invested capital, and it fits well in our existing bedrock business operations"
President Donald Trump declared opioid misuse in the US as a national public health emergency earlier this year
Paul Devlin played a "significant role" throughout the group's fundraise used for the acquisition of CellRight Technologies
The trial will evaluate the effectiveness of an injectable HIV drug, administered only once every two months, in sexually active women
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.
Data from 40 men will determine the doses used in the final-stage clinical assessment MED2002
This is a significant milestone for the company as it will generate long-term revenues with management expecting income of £500,000 to be realised in the first 12 months.
The company's Parsortix device was able to isolate circulating tumour cells in high purity without the need to separate them out
Rather than making regular cash pay-outs, the company wants to be able to sanction a “dividend in specie” that would allow it to distribute its holding in SkinBioTherapeutics
Shares in Glaxo SmithKline rose 2% after phase III trials were announced and after an upgrade by Swiss bank UBS
Uncertainty surrounding the trajectory of GSK’s ViiV Healthcare HIV business justifies a discount argues UBS analyst Michael Leutchen, but he reckons the valuation now reflects that